Cargando…
Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia
To investigate the efficacy of eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C, a phase II, single-arm, open-label study with a 9-week pre-antiviral phase was conducted, followed by a 48-week antiviral phase and a 24-week follow-up phase. The proportion of pati...
Autores principales: | Kawaguchi, Takumi, Komori, Atsumasa, Fujisaki, Kunio, Nishiguchi, Shuhei, Kato, Michio, Takagi, Hitoshi, Tanaka, Yasuhito, Notsumata, Kazuo, Mita, Eiji, Nomura, Hideyuki, Shibatoge, Mitsushige, Takaguchi, Koichi, Hattori, Toshihiro, Sata, Michio, Koike, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566053/ https://www.ncbi.nlm.nih.gov/pubmed/31258695 http://dx.doi.org/10.3892/etm.2019.7616 |
Ejemplares similares
-
Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study
por: Kawaguchi, Takumi, et al.
Publicado: (2012) -
Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin
por: Toyoda, Hidenori, et al.
Publicado: (2012) -
Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013) -
Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases
por: KAWAGUCHI, TAKUMI, et al.
Publicado: (2014) -
Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)